Core Scientific (CORZW) Common Equity (2020 - 2026)

Core Scientific's Common Equity history runs 7 years deep, the most recent figure standing at -$1.3 billion for Q1 2026.

• In Q1 2026, Common Equity fell 322.8% year-over-year to -$1.3 billion; the TTM figure through Mar 2026 stood at -$1.3 billion (down 322.8% YoY), while the FY2025 annual figure was -$962.7 million, down 2.09% from the prior year.
• Common Equity came in at -$1.3 billion for Q1 2026 at Core Scientific, down from -$962.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.1 billion in Q1 2022 to a low of -$1.3 billion in Q1 2026.
• A 5-year average of -$522.9 million and a median of -$418.7 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 1059.68% in 2022 and sank 673.39% in 2023, its largest moves.
• Core Scientific's Common Equity stood at -$409.3 million in 2022, then sank by 45.83% to -$596.9 million in 2023, then tumbled by 57.98% to -$943.0 million in 2024, then fell by 2.09% to -$962.7 million in 2025, then slumped by 35.62% to -$1.3 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$1.3 billion, -$962.7 million, and -$1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison